drugwatch®

A Patient's Guide to Zantac

NDMA Exposure, Nationwide Recalls and Lawsuit Information

Table of Contents

From this guide, you will learn:

- Why Zantac is no longer available in the U.S.
- How ranitidine products could expose consumers to unacceptable health risks
- Who is eligible to file a Zantac lawsuit

Introduction

If you are one of millions of Americans who suffer from acid indigestion, GERD or ulcers, you may have taken over-the-counter or prescription Zantac or its generic form, ranitidine.

Zantac had been a popular heartburn drug for more than 35 years when the Food and Drug Administration asked companies to stop selling all forms of the medication in April 2020.

According to the FDA, a potential cancer-causing contaminant called N-Nitrosodimethylamine (NDMA) can build up in ranitidine over time, posing a risk to consumers. The FDA does not know how long NDMA has been present in ranitidine products.

15 Million Americans

had taken prescription-strength Zantac or ranitidine each year prior to the market withdrawal in April 2020

500+ Lawsuits

claim manufacturers concealed the NDMA-associated dangers that ranitidine products posed to consumers

35 Years

elapsed before manufacturers began recalling ranitidine products because they may contain unacceptable levels of NDMA

Zantac Recalls

In September 2019, the FDA warned that some batches of ranitidine had tested positive for NDMA. After the FDA's warning, manufacturers began recalling ranitidine products.

Further laboratory testing revealed that NDMA in ranitidine may increase to unacceptable levels when stored for long periods and when exposed to higher than room temperatures.

> "Based on these findings, FDA has determined that many currently marketed ranitidine products could expose consumers to unacceptable health risks. All ranitidine products, including the oral liquid/syrup, will be withdrawn by their manufacturers and will not be available on the U.S. market."
>
> — Food and Drug Administration

Should I Stop Taking Zantac?

The FDA advises people who currently have OTC Zantac or ranitidine to stop using it right away. People taking prescription Zantac or ranitidine should speak with their doctor about other treatment options. Ranitidine products are not available for new or existing prescriptions or over-the-counter use in the U.S.



How Dangerous Is NDMA in Zantac?

Small amounts of NDMA exist in food, water and the environment and aren't typically a danger. But chronic exposure to high levels of NDMA — like those found in some batches of Zantac — could increase the risk of developing various cancers.

While researchers don't know how high the risk is, some studies have linked ranitidine to cancers.

Symptoms of NDMA overexposure include:

- Abdominal cramps
- Dizziness
- Enlarged liver
- Fever
- Headaches
- Jaundice
- Nausea
- Reduced function of the liver, kidneys and lungs
- Vomiting

Current Lawsuits

Hundreds of people have already filed Zantac lawsuits to hold drugmakers accountable for exposing them to NDMA. Doctors have said most people who developed cancer and filed lawsuits had no family history or genetic markers for the disease.

Lawsuits claim that Zantac's makers knew or should have known that the drug could potentially form NDMA and become a cancer risk, and they didn't warn the public.

> "Plaintiffs uniformly allege that the manufacturers, sellers, and distributors of Zantac and other ranitidine medications knew or should have known that these medications exposed consumers to NDMA, and that defendants concealed the NDMA-associated dangers posed to consumers by these products."
>
> — United States Judicial Panel on Multidistrict Litigation

Am I Eligible to File a Lawsuit?

If you or a loved one were diagnosed with cancer after taking Zantac, you may qualify to file a lawsuit for compensation. A lawyer can review your case for free and help gather medical records to build a case.

Cancers that qualify for Zantac lawsuits include:

- Bladder cancer and bladder removal
- Breast cancer
- Colon cancer
- Esophageal cancer
- Kidney cancer and kidney removal
- Liver cancer
- Melanoma
- Ovarian cancer
- Prostate cancer
- Stomach cancer

Questions Your Zantac Lawyer May Ask

What have you been diagnosed with?

The lawyer handling your case will want to know what type of cancer you were diagnosed with and when. Medical records showing the diagnosis are helpful.

How long did you take Zantac?

Do your best to remember when you started taking the drug. If you have any documentation to prove you took Zantac, your lawyer will need the records.

How are you being treated for your cancer?

Your lawyer will want to know what type of treatment you are undergoing for your cancer, how you are feeling and if it's working.

Do you have a personal or family history of cancer?

If you or a member of your family have had cancer before, you may be more at risk of developing it again. Provide a copy of your medical records and be ready to discuss your family's medical history.

Patient Checklist

Items to Have Ready for Your Free Consultation

- ☑ Medical Records & Family History
- ☑ List of Medications and Cancer Treatments
- ☑ Record of Zantac Use

Sources

Food and Drug Administration. (2020, September 3). Questions and Answers: NDMA impurities in metformin products. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/questions-and-answers-ndma-impurities-metformin-products

Food and Drug Administration. (2020, April 1). FDA Requests Removal of All Ranitidine Products (Zantac) from the Market. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market

Food and Drug Administration. (2020, February 27). FDA Updates and Press Announcements on NDMA in Zantac (ranitidine). Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine

Food and Drug Administration. (2019, September 13). Statement alerting patients and health care professionals of NDMA found in samples of ranitidine. Retrieved from https://www.fda.gov/news-events/press-announcements/statement-alerting-patients-and-health-care-professionals-ndma-found-samples-ranitidine

Marill, M.C. (2020, January 10). The FDA Announces Two More Antacid Recalls Due to Cancer Risk. Retrieved from https://www.wired.com/story/the-fda-announces-two-more-antacid-recalls-due-to-cancer-risk/

United States Environmental Protection Agency. (2014). Technical Fact Sheet – N-Nitroso-dimethylamine (NDMA). Retrieved from https://www.epa.gov/sites/production/files/2014-03/documents/ffrrofactsheet_contaminant_ndma_january2014_final.pdf

United States Judicial Panel on Multidistrict Litigation. (2020, November 16). MDL Statistics Report - Distribution of Pending MDL Dockets by Actions Pending. Retrieved from https://www.jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_Actions_Pending-November-16-2020.pdf

United States Judicial Panel on Multidistrict Litigation. (2020, February 6). Transfer Order. Retrieved from https://www.jpml.uscourts.gov/sites/jpml/files/MDL-2924-Transfer%20Order-1-20.pdf

Contributors

Michelle Llamas

Senior Writer, Drugwatch

Michelle Llamas is a member of the American Medical Writers Association and a former legal assistant for plaintiff's injury law firms.

Sophia Clifton

Editor, Drugwatch

Sophia Clifton holds a Bachelor of Arts in English and five health literacy certificates from the Centers for Disease Control and Prevention.